Investigating the effect of rosuvastatin in patients with human immunodeficiency virus (HIV)
Phase 1
- Conditions
- Patients with human immunodeficiency virus.Acquired immunodeficiency syndrome [AIDS] NOSAIDS-related complex [ARC] NOS
- Registration Number
- IRCT20231124060158N1
- Lead Sponsor
- Iran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 69
Inclusion Criteria
Lack of immunological response, suitable virological response
receiving rosuvastatin treatment
willingness of the patient to cooperate in the study and fill in the informed consent form -
HIV infection
age at least 18 years
Exclusion Criteria
Patients' lack of consent to participate in the study
Non-cooperation of patients
Lack of adequate virologic response
Having an immunological response
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Determining the immunological effect of statin in HIV+ patients with adequate virological response and no immunological response. Timepoint: The effect of rosuvastatin in patients after 90 days and based on CD4 measured before and after the treatment is determined and compared in patients based on other variables. Method of measurement: Measurement of CD4 before and after treatment through patients' blood samples.
- Secondary Outcome Measures
Name Time Method